Publications

SMARCA4 deficient Uterine sarcoma is a rare but highly aggressive sarcoma.

Diagnostic dilemma is the major hurdle.

Germline testing warranted to identify hereditary syndrome (RTPS).

Established chemotherapeutic guidelines for SDUS is sparse.

Gemcitabine-taxol based regimen yielded significant clinic-radiological benefit.